Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 1;63(10):e724-e731.
doi: 10.1097/JOM.0000000000002354.

Impact of Medication Adherence on Healthcare Resource Utilization, Work Loss, and Associated Costs in a Privately Insured Employed Population Treated With Adalimumab in the United States

Manish Mittal  1 , Min Yang, Manan Shah, Wei Gao, Christopher Carley, Bruce W Sherman
Affiliations

Impact of Medication Adherence on Healthcare Resource Utilization, Work Loss, and Associated Costs in a Privately Insured Employed Population Treated With Adalimumab in the United States

Manish Mittal et al. J Occup Environ Med. .

Abstract

Objective: The aim of this study was to evaluate the impact of adherence to adalimumab on all-cause work loss, healthcare resource utilization (HRU), and direct medical and indirect costs over 2 years using real-world data.

Methods: This was a retrospective cohort study using a large, United States administrative claims database. Adult patients treated with adalimumab were grouped into adherent and non-adherent cohorts and followed for up to 2 years. Outcomes were compared between cohorts.

Results: Over 2 years, adherent patients had $10,214 lower per patient medical and indirect costs compared to non-adherent patients, resulting from lower HRU, fewer days of absenteeism, and lower rates of work loss events.

Conclusion: Patient and societal benefits of adherence to adalimumab are significant over 2 years. These findings highlight the importance of policies aimed at improving adherence to self-administrated medications.

PubMed Disclaimer

Conflict of interest statement

Manish Mittal and Manan Shah are employees of AbbVie, Inc. and own stock/stock options. Min Yang, Wei Gao, and Christopher Carley are employees of Analysis Group Inc., which has received consultancy fees from AbbVie, Inc. Bruce Sherman declares no conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

FIGURE 1
FIGURE 1
Study design. Note: (∗) In the post-index study period, patients were followed until disenrollment or the end of the study period, whichever came first.
FIGURE 2
FIGURE 2
Sample selection. ICD-9 (10)-CM, International Classification of Diseases – Ninth (Tenth) edition – Clinical Modification; Q1, first quarter. Notes: (a) Diagnoses were identified by ICD-9-CM or ICD-10-CM codes listed as either the primary or secondary diagnosis code in the medical claims database; (b) For patients with multiple indications, index therapeutic area was assigned according to the most recent diagnosis prior to the index date.
FIGURE 3
FIGURE 3
Healthcare costs among patients with high versus low adherence to adalimumab. PPPY, per patient per year; USD, United States dollars.
See this image and copyright information in PMC

References

    1. Peterson A, Takiya L, Finley R. Meta-analysis of trials of interventions to improve medication adherence. Am J Health Syst Pharm 2003; 60:657–665. - PubMed
    1. Nieuwlaat R, Wilczynski N, Navarro T, et al. . Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2014; 2014:CD000011. - PMC - PubMed
    1. Mahoney J, Ansell B, Facc F, Fleming W, Butterworth S. The unhidden cost of noncompliance. J Manag Care Spec Pharm 2008; 14:S1–S29.
    1. Viswanathan M, Golin C, Jones C, et al. . Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med 2012; 157:785–795. - PubMed
    1. Cutler R, Fernandez-Llimos F, Frommer M, Benrimoj S, Garcia-Cardenas V. Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open 2018; 8:e016982. - PMC - PubMed

Publication types